A vaccine to prevent infections caused by Klebsiella pneumoniae
Official title: A multivalent O-antigen bioconjugate vaccine for the prevention of Klebsiella pneumoniae infections
Funded at Vaxnewmo, LLC · NIH-11094220 · Data updated 2026-11-12
This study is testing a new vaccine designed to help protect people from serious infections caused by a tough bacteria called Klebsiella pneumoniae, and it aims to make the vaccine easier to produce while boosting your immune response.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vaxnewmo, LLC NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | July 15, 2022 |
| Project end | July 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $994,178 |
| NIH project number | 4R42AI165116-03 |
| Project ID | NIH-11094220 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals at high risk for Klebsiella pneumoniae infections, such as those with weakened immune systems or those undergoing certain medical procedures.
✕Less likely to help
Patients who are not at risk for Klebsiella pneumoniae infections or those who have already been vaccinated against it may not benefit from this research.
What this research studies
This research focuses on developing a new vaccine to protect against Klebsiella pneumoniae, a bacteria that causes serious infections and is often resistant to antibiotics. The approach involves creating a multivalent conjugate vaccine that targets various strains of the bacteria, using a novel method called bioconjugation that simplifies the vaccine manufacturing process. By linking bacterial polysaccharides to carrier proteins, this vaccine aims to enhance the immune response and provide better protection against infections. Patients may be involved in trials to evaluate the vaccine's safety and effectiveness.
Why it matters
Potential benefit: If successful, this research could lead to a new vaccine that significantly reduces the incidence of Klebsiella pneumoniae infections, especially in vulnerable populations.
How similar studies have gone: Other research has shown success with similar conjugate vaccine approaches, indicating potential for this novel method to be effective as well.
Where this research is happening
-
Vaxnewmo, LLC
Saint Louis, United States Active
Researchers
- Principal investigator: Harding, Christian — Vaxnewmo, LLC
- Study coordinator: Harding, Christian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.